Baxter presents EBP research at ASN Kidney Week

Baxter International recently presented its research on extracorporeal blood purification (EBP) and its role in the removing of molecules associated with inflammation at the American Society of Nephrology’s annual Kidney Week.
“Baxter continues to build on its commitment to contribute meaningful research to advance acute and chronic blood therapies,” Baxter Vice President of Medical Affairs Dr. Dheerendra Kommala said. “This exploratory research adds to the body of knowledge in an important area that is not fully understood – the treatment of inflammation-related conditions in chronic kidney disease and critically ill ICU patients.”
EBP is a blood purification technique that is administered outside the body. Within the extracorporeal circuit, blood passes through a membrane, which sees the filtering out of the blood harmful molecules and waste products and returns the blood to its normal state. Once the blood is clean, it is returned to the body.
“While our findings conclude that targeting these molecules is possible, further research will help us understand the clinical impact of removing these molecules from the blood,” Baxter Senior R&D Manager Markus Storr said.